LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 321

Search options

  1. Article ; Online: Adapting vector surveillance using Bayesian experimental design: An application to an ongoing tick monitoring program in the southeastern United States.

    Case, B K M / Dye-Braumuller, Kyndall C / Evans, Chris / Li, Huixuan / Rustin, Lauren / Nolan, Melissa S

    Ticks and tick-borne diseases

    2024  Volume 15, Issue 3, Page(s) 102329

    Abstract: Maps of the distribution of medically-important ticks throughout the US remain lacking in spatial and temporal resolution in many areas, leading to holes in our understanding of where and when people are at risk of tick encounters, an important baseline ... ...

    Abstract Maps of the distribution of medically-important ticks throughout the US remain lacking in spatial and temporal resolution in many areas, leading to holes in our understanding of where and when people are at risk of tick encounters, an important baseline for informing public health response. In this work, we demonstrate the use of Bayesian Experimental Design (BED) in planning spatiotemporal surveillance of disease vectors. We frame survey planning as an optimization problem with the objective of identifying a calendar of sampling locations that maximizes the expected information regarding some goal. Here we consider the goals of understanding associations between environmental factors and tick presence and minimizing uncertainty in high risk areas. We illustrate our proposed BED workflow using an ongoing tick surveillance study in South Carolina parks. Following a model comparison study based on two years of initial data, several techniques for finding optimal surveys were compared to random sampling. Two optimization algorithms found surveys better than all replications of random sampling, while a space-filling heuristic performed favorably as well. Further, optimal surveys of just 20 visits were more effective than repeating the schedule of 111 visits used in 2021. We conclude that BED shows promise as a flexible and rigorous means of survey design for vector control, and could help alleviate pressure on local agencies by limiting the resources necessary for accurate information on arthropod distributions. We have made the code for our BED workflow publicly available on Zenodo to help promote the application of these methods to future surveillance efforts.
    MeSH term(s) Animals ; Humans ; United States ; Ticks ; Bayes Theorem ; Southeastern United States/epidemiology
    Language English
    Publishing date 2024-03-13
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2541872-5
    ISSN 1877-9603 ; 1877-959X
    ISSN (online) 1877-9603
    ISSN 1877-959X
    DOI 10.1016/j.ttbdis.2024.102329
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data.

    Rustin, M H A

    The British journal of dermatology

    2012  Volume 167 Suppl 3, Page(s) 3–11

    Abstract: Conventional non-biologic systemic agents are regarded as second-line therapy for the treatment of moderate-to-severe plaque psoriasis after topical treatments. However, long-term data have highlighted a number of safety concerns associated with their ... ...

    Abstract Conventional non-biologic systemic agents are regarded as second-line therapy for the treatment of moderate-to-severe plaque psoriasis after topical treatments. However, long-term data have highlighted a number of safety concerns associated with their prolonged use. Biologic agents targeting specific immune mediators have emerged as an alternative treatment option for patients with moderate-to-severe plaque psoriasis who are unresponsive to, or intolerant of, non-biologic systemic agents. Although several biologics have demonstrated good efficacy and tolerability in short-term trials, treatment guidelines recommend them as third-line therapies due to a relative lack of long-term safety data. Here, we have reviewed the long-term (≥ 1 year) safety data from randomized controlled trials, open-label extension studies and meta-analyses of etanercept, infliximab, efalizumab, adalimumab, alefacept and ustekinumab in the treatment of adults with moderate-to-severe plaque psoriasis. With the exception of efalizumab, which has been withdrawn from both the European and U.S. markets due to long-term safety concerns, these biologics are generally well tolerated in long-term studies, and offer a viable alternative to conventional non-biologic agents in patients with moderate-to-severe plaque psoriasis.
    MeSH term(s) Antibodies, Monoclonal/adverse effects ; Biological Products/adverse effects ; Dermatologic Agents/adverse effects ; Female ; HIV Infections/complications ; Hepatitis B, Chronic/complications ; Hepatitis C, Chronic/complications ; Humans ; Pregnancy ; Pregnancy Complications/drug therapy ; Preoperative Care/methods ; Psoriasis/drug therapy ; Randomized Controlled Trials as Topic ; Recombinant Fusion Proteins/adverse effects
    Chemical Substances Antibodies, Monoclonal ; Biological Products ; Dermatologic Agents ; Recombinant Fusion Proteins
    Language English
    Publishing date 2012-11
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 80076-4
    ISSN 1365-2133 ; 0007-0963
    ISSN (online) 1365-2133
    ISSN 0007-0963
    DOI 10.1111/j.1365-2133.2012.11208.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Unusual skin changes on the neck.

    Lock, A D / Deroide, F / Rustin, M H A / Jolliffe, V

    Clinical and experimental dermatology

    2017  Volume 42, Issue 3, Page(s) 351–353

    MeSH term(s) Aged ; Biopsy ; Female ; Humans ; Middle Aged ; Neck/pathology ; Pseudoxanthoma Elasticum/pathology ; Skin/pathology
    Language English
    Publishing date 2017-01-10
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 195504-4
    ISSN 1365-2230 ; 0307-6938
    ISSN (online) 1365-2230
    ISSN 0307-6938
    DOI 10.1111/ced.13031
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review.

    Rustin, M H A

    The British journal of dermatology

    2007  Volume 157, Issue 5, Page(s) 861–873

    Abstract: Tacrolimus ointment is a topical calcineurin inhibitor (TCI) that was developed specifically for the treatment of atopic dermatitis (AD). It is one of the most extensively tested dermatological products, with more than 19 000 patients (including ... ...

    Abstract Tacrolimus ointment is a topical calcineurin inhibitor (TCI) that was developed specifically for the treatment of atopic dermatitis (AD). It is one of the most extensively tested dermatological products, with more than 19 000 patients (including approximately 7600 children) having participated in the tacrolimus ointment clinical development programme. Recent regulatory reviews have focused on the potential risk of malignancy with TCIs, based on their mode of action and the effects of systemic tacrolimus when given to transplant recipients. Studies have shown, however, that the systemic absorption of tacrolimus when applied topically is very low, with blood concentrations being below the level of quantification in most patients. Moreover, TCIs are not associated with a decrease in immunocompetence in the skin and there is no increase in the incidence of infections with long-term treatment. More than 5.4 million prescriptions for tacrolimus ointment have been issued worldwide, with no evidence of an increased risk of malignancy in adults or children compared with the general population. Similarly, epidemiological studies have failed to demonstrate an increased incidence of skin cancer in patients using TCIs. The most common adverse events (AEs) that occur with tacrolimus ointment treatment are transient application-site reactions, such as burning or pruritus. These complications are related to disease severity, and decrease in frequency over time as AD improves. The incidence of nonapplication-site AEs does not increase with long-term treatment, and most such events occurring in clinical trials were considered to be unrelated to therapy. Although it is important that clinicians are aware of the recent changes in product labelling, extensive clinical trials continue to show that tacrolimus ointment is well tolerated, and is generally an effective therapy for suitable patients with AD.
    MeSH term(s) Administration, Topical ; Dermatitis, Atopic/drug therapy ; Dermatologic Agents/adverse effects ; Humans ; Immunosuppressive Agents/adverse effects ; Ointments ; Skin Neoplasms/chemically induced ; Tacrolimus/adverse effects ; Treatment Outcome
    Chemical Substances Dermatologic Agents ; Immunosuppressive Agents ; Ointments ; Tacrolimus (WM0HAQ4WNM)
    Language English
    Publishing date 2007-11
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 80076-4
    ISSN 1365-2133 ; 0007-0963
    ISSN (online) 1365-2133
    ISSN 0007-0963
    DOI 10.1111/j.1365-2133.2007.08177.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Sustained improvement in urticaria pigmentosa and pruritus in a case of indolent systemic mastocytosis treated with cladribine.

    Lock, A D / McNamara, C J / Rustin, M H A

    Clinical and experimental dermatology

    2015  Volume 40, Issue 2, Page(s) 142–145

    Abstract: Systemic mastocytosis (SM) is a myeloproliferative disorder, characterized by a clonal proliferation of abnormal mast cells accumulating in internal organs and sometimes in the skin, leading to cutaneous and systemic symptoms. Mutations within the gene ... ...

    Abstract Systemic mastocytosis (SM) is a myeloproliferative disorder, characterized by a clonal proliferation of abnormal mast cells accumulating in internal organs and sometimes in the skin, leading to cutaneous and systemic symptoms. Mutations within the gene KIT, which encodes the receptor tyrosine kinase (KIT) on mast cells, is found in most patients with SM. We report a case of a 62-year-old woman presenting with a pruritic rash on her limbs and trunk. Several years later she developed gastrointestinal symptoms, associated with raised serum tryptase. Skin and bone marrow biopsies confirmed a diagnosis of SM, initially presenting with urticaria pigmentosa. Responses to multiple therapies, including potent topical steroids, oral antihistamines, phototherapy and the tyrosine kinase inhibitor, nilotinib, were inadequate. Treatment with cladribine (2-chlorodeoxyadenosine) produced a marked and sustained reduction in her symptoms and serum tryptase level.
    MeSH term(s) Cladribine/therapeutic use ; Female ; Humans ; Immunosuppressive Agents/therapeutic use ; Mastocytosis, Systemic/drug therapy ; Middle Aged ; Pruritus/drug therapy ; Treatment Outcome ; Urticaria Pigmentosa/drug therapy
    Chemical Substances Immunosuppressive Agents ; Cladribine (47M74X9YT5)
    Language English
    Publishing date 2015-03
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 195504-4
    ISSN 1365-2230 ; 0307-6938
    ISSN (online) 1365-2230
    ISSN 0307-6938
    DOI 10.1111/ced.12488
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.

    Ledermann, J A / Embleton-Thirsk, A C / Perren, T J / Jayson, G C / Rustin, G J S / Kaye, S B / Hirte, H / Oza, A / Vaughan, M / Friedlander, M / González-Martín, A / Deane, E / Popoola, B / Farrelly, L / Swart, A M / Kaplan, R S / Parmar, M K B

    ESMO open

    2021  Volume 6, Issue 2, Page(s) 100043

    Abstract: Background: Cediranib, an oral anti-angiogenic VEGFR 1-3 inhibitor, was studied at a daily dose of 20 mg in combination with platinum-based chemotherapy and as maintenance in a randomised trial in patients with first relapse of 'platinum-sensitive' ... ...

    Abstract Background: Cediranib, an oral anti-angiogenic VEGFR 1-3 inhibitor, was studied at a daily dose of 20 mg in combination with platinum-based chemotherapy and as maintenance in a randomised trial in patients with first relapse of 'platinum-sensitive' ovarian cancer and has been shown to improve progression-free survival (PFS).
    Patients and methods: ICON6 (NCT00532194) was an international three-arm, double-blind, placebo-controlled randomised trial. Between December 2007 and December 2011, 456 women were randomised, using stratification, to receive either chemotherapy with placebo throughout (arm A, reference); chemotherapy with concurrent cediranib, followed by maintenance placebo (arm B, concurrent); or chemotherapy with concurrent cediranib, followed by maintenance cediranib (arm C, maintenance). Due to an enforced redesign of the trial in September 2011, the primary endpoint became PFS between arms A and C which we have previously published, and the overall survival (OS) was defined as a secondary endpoint, which is reported here.
    Results: After a median follow-up of 25.6 months, strong evidence of an effect of concurrent plus maintenance cediranib on PFS was observed [hazard ratio (HR) 0.56, 95% confidence interval (CI) 0.44-0.72, P < 0.0001]. In this final update of the survival analysis, 90% of patients have died. There was a 7.4-month difference in median survival and an HR of 0.86 (95% CI: 0.67-1.11, P = 0.24) in favour of arm C. There was strong evidence of a departure from the assumption of non-proportionality using the Grambsch-Therneau test (P = 0.0031), making the HR difficult to interpret. Consequently, the restricted mean survival time (RMST) was used and the estimated difference over 6 years by the RMST was 4.8 months (95% CI: -0.09 to 9.74 months).
    Conclusions: Although a statistically significant difference in time to progression was seen, the enforced curtailment in recruitment meant that the secondary analysis of OS was underpowered. The relative reduction in the risk of death of 14% risk of death was not conventionally statistically significant, but this improvement and the increase in the mean survival time in this analysis suggest that cediranib may have worthwhile activity in the treatment of recurrent ovarian cancer and that further research should be undertaken.
    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Female ; Humans ; Neoplasm Recurrence, Local/drug therapy ; Ovarian Neoplasms/drug therapy ; Quinazolines/therapeutic use
    Chemical Substances Quinazolines ; cediranib (NQU9IPY4K9)
    Language English
    Publishing date 2021-02-18
    Publishing country England
    Document type Clinical Trial, Phase III ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ISSN 2059-7029
    ISSN (online) 2059-7029
    DOI 10.1016/j.esmoop.2020.100043
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Transcranial focused ultrasound selectively increases perfusion and modulates functional connectivity of deep brain regions in humans.

    Kuhn, Taylor / Spivak, Norman M / Dang, Bianca H / Becerra, Sergio / Halavi, Sabrina E / Rotstein, Natalie / Rosenberg, Benjamin M / Hiller, Sonja / Swenson, Andrew / Cvijanovic, Luka / Dang, Nolan / Sun, Michael / Kronemyer, David / Berlow, Rustin / Revett, Malina R / Suthana, Nanthia / Monti, Martin M / Bookheimer, Susan

    Frontiers in neural circuits

    2023  Volume 17, Page(s) 1120410

    Abstract: Background: Low intensity, transcranial focused ultrasound (tFUS) is a re-emerging brain stimulation technique with the unique capability of reaching deep brain structures non-invasively.: Objective/hypothesis: We sought to demonstrate that tFUS can ... ...

    Abstract Background: Low intensity, transcranial focused ultrasound (tFUS) is a re-emerging brain stimulation technique with the unique capability of reaching deep brain structures non-invasively.
    Objective/hypothesis: We sought to demonstrate that tFUS can selectively and accurately target and modulate deep brain structures in humans important for emotional functioning as well as learning and memory. We hypothesized that tFUS would result in significant longitudinal changes in perfusion in the targeted brain region as well as selective modulation of BOLD activity and BOLD-based functional connectivity of the target region.
    Methods: In this study, we collected MRI before, simultaneously during, and after tFUS of two deep brain structures on different days in sixteen healthy adults each serving as their own control. Using longitudinal arterial spin labeling (ASL) MRI and simultaneous blood oxygen level dependent (BOLD) functional MRI, we found changes in cerebral perfusion, regional brain activity and functional connectivity specific to the targeted regions of the amygdala and entorhinal cortex (ErC).
    Results: tFUS selectively increased perfusion in the targeted brain region and not in the contralateral homolog or either bilateral control region. Additionally, tFUS directly affected BOLD activity in a target specific fashion without engaging auditory cortex in any analysis. Finally, tFUS resulted in selective modulation of the targeted functional network connectivity.
    Conclusion: We demonstrate that tFUS can selectively modulate perfusion, neural activity and connectivity in deep brain structures and connected networks. Lack of auditory cortex findings suggests that the mechanism of tFUS action is not due to auditory or acoustic startle response but rather a direct neuromodulatory process. Our findings suggest that tFUS has the potential for future application as a novel therapy in a wide range of neurological and psychiatric disorders associated with subcortical pathology.
    MeSH term(s) Adult ; Humans ; Brain Mapping/methods ; Reflex, Startle ; Brain/diagnostic imaging ; Brain/physiology ; Magnetic Resonance Imaging/methods ; Perfusion
    Language English
    Publishing date 2023-04-05
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2452968-0
    ISSN 1662-5110 ; 1662-5110
    ISSN (online) 1662-5110
    ISSN 1662-5110
    DOI 10.3389/fncir.2023.1120410
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Recruitment of inflammatory monocytes by senescent fibroblasts inhibits antigen-specific tissue immunity during human aging.

    Chambers, Emma S / Vukmanovic-Stejic, Milica / Shih, Barbara B / Trahair, Hugh / Subramanian, Priya / Devine, Oliver P / Glanville, James / Gilroy, Derek / Rustin, Malcolm H A / Freeman, Tom C / Mabbott, Neil A / Akbar, Arne N

    Nature aging

    2021  Volume 1, Issue 1, Page(s) 101–113

    Abstract: We have previously shown that healthy older adults exhibit reduced cutaneous immune responses during a varicella zoster virus (VZV) antigen challenge that correlated with a nonspecific inflammatory response to the injection itself. Here we found that ... ...

    Abstract We have previously shown that healthy older adults exhibit reduced cutaneous immune responses during a varicella zoster virus (VZV) antigen challenge that correlated with a nonspecific inflammatory response to the injection itself. Here we found that needle damage during intradermal injections in older adults led to an increase in the number of cutaneous senescent fibroblasts expressing CCL2, resulting in the local recruitment of inflammatory monocytes. These infiltrating monocytes secreted prostaglandin E2, which inhibited resident memory T cell activation and proliferation. Pretreatment of older participants with a p38 mitogen-activated protein kinase inhibitor in vivo decreased CCL2 expression and inhibited monocyte recruitment and secretion of prostaglandin E2. This coincided with an increased response to VZV antigen challenge in the skin. Our results point to a series of molecular and cellular mechanisms that link cellular senescence, tissue damage, excessive inflammation and reduced immune responsiveness in human skin and demonstrate that tissue-specific immunity can be restored in older adults by short-term inhibition of inflammatory responses.
    MeSH term(s) Humans ; Aged ; Monocytes ; Dinoprostone/metabolism ; Aging ; Herpesvirus 3, Human ; Lymphocyte Activation ; Fibroblasts
    Chemical Substances Dinoprostone (K7Q1JQR04M)
    Language English
    Publishing date 2021-01-14
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2662-8465
    ISSN (online) 2662-8465
    DOI 10.1038/s43587-020-00010-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.

    Hall, M R / Dehbi, H-M / Banerjee, S / Lord, R / Clamp, A / Ledermann, J A / Nicum, S / Lilleywhite, R / Bowen, R / Michael, A / Feeney, A / Glasspool, R / Hackshaw, A / Rustin, G

    Gynecologic oncology

    2020  Volume 159, Issue 3, Page(s) 692–698

    Abstract: Background: We investigated the safety and efficacy of a combination of the oral tyrosine kinase inhibitor, nintedanib (BIBF 1120) with oral cyclophosphamide in patients with relapsed ovarian cancer.: Patients and methods: Patients with relapsed ... ...

    Abstract Background: We investigated the safety and efficacy of a combination of the oral tyrosine kinase inhibitor, nintedanib (BIBF 1120) with oral cyclophosphamide in patients with relapsed ovarian cancer.
    Patients and methods: Patients with relapsed ovarian, fallopian tube or primary peritoneal cancer received oral cyclophosphamide (100 mg o.d.) and were randomised (1,1) to also have either oral nintedanib or placebo. The primary endpoint was overall survival (OS). Secondary endpoints included progression free survival (PFS), response rate, toxicity, and quality of life.
    Results: 117 patients were randomised, 3 did not start trial treatment, median age 64 years. Forty-five (39%) had received ≥5 lines chemotherapy. 30% had received prior bevacizumab. The median OS was 6.8 (nintedanib) versus 6.4 (placebo) months (hazard ratio 1.08; 95% confidence interval 0.72-1.62; P = 0.72). The 6-month PFS rate was 29.6% versus 22.8% (P = 0.57). Grade 3/4 adverse events occurred in 64% (nintedanib) versus 54% (placebo) of patients (P = 0.28); the most frequent G3/4 toxicities were lymphopenia (18.6% nintedanib versus 16.4% placebo), diarrhoea (13.6% versus 0%), neutropenia (11.9% versus 0%), fatigue (10.2% versus 9.1%), and vomiting (10.2% versus 7.3%). Patients who had received prior bevacizumab treatment had 52 days less time on treatment (P < 0.01). 26 patients (23%) took oral cyclophosphamide for ≥6 months. There were no differences in quality of life between treatment arms.
    Conclusions: This is the largest reported cohort of patients with relapsed ovarian cancer treated with oral cyclophosphamide. Nintedanib did not improve outcomes when added to oral cyclophosphamide. Although not significant, more patients than expected remained on treatment for ≥6 months. This may reflect a higher proportion of patients with more indolent disease or the higher dose of cyclophosphamide used.
    Clinical trial registration: Clinicaltrials.govNCT01610869.
    MeSH term(s) Administration, Metronomic ; Administration, Oral ; Aged ; Angiogenesis Inhibitors/administration & dosage ; Angiogenesis Inhibitors/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Fallopian Tube Neoplasms/diagnosis ; Fallopian Tube Neoplasms/drug therapy ; Fallopian Tube Neoplasms/mortality ; Fallopian Tube Neoplasms/pathology ; Female ; Humans ; Indoles/administration & dosage ; Indoles/adverse effects ; Middle Aged ; Neoplasm Staging ; Ovarian Neoplasms/diagnosis ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/mortality ; Ovarian Neoplasms/pathology ; Peritoneal Neoplasms/diagnosis ; Peritoneal Neoplasms/drug therapy ; Peritoneal Neoplasms/mortality ; Peritoneal Neoplasms/pathology ; Progression-Free Survival ; Quality of Life
    Chemical Substances Angiogenesis Inhibitors ; Indoles ; Cyclophosphamide (8N3DW7272P) ; nintedanib (G6HRD2P839)
    Language English
    Publishing date 2020-10-16
    Publishing country United States
    Document type Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 801461-9
    ISSN 1095-6859 ; 0090-8258
    ISSN (online) 1095-6859
    ISSN 0090-8258
    DOI 10.1016/j.ygyno.2020.09.048
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Vitamin D

    Chambers, Emma S / Vukmanovic-Stejic, Milica / Turner, Carolin T / Shih, Barbara B / Trahair, Hugh / Pollara, Gabriele / Tsaliki, Evdokia / Rustin, Malcolm / Freeman, Tom C / Mabbott, Neil A / Noursadeghi, Mahdad / Martineau, Adrian R / Akbar, Arne N

    Immunotherapy advances

    2020  Volume 1, Issue 1, Page(s) ltaa008

    Abstract: Introduction: Ageing is associated with increased number of infections, decreased vaccine efficacy and increased systemic inflammation termed inflammageing. These changes are reflected by reduced recall responses to varicella zoster virus (VZV) ... ...

    Abstract Introduction: Ageing is associated with increased number of infections, decreased vaccine efficacy and increased systemic inflammation termed inflammageing. These changes are reflected by reduced recall responses to varicella zoster virus (VZV) challenge in the skin of older adults. Vitamin D deficiency is more common in the old and has been associated with frailty and increased inflammation. In addition, vitamin D increases immunoregulatory mechanisms and therefore has the potential to inhibit inflammageing.
    Objectives: We investigated the use of vitamin D
    Methods: Vitamin D insufficient older adults (
    Results: We showed that older adults had reduced VZV-specific cutaneous immune response and increased non-specific inflammation as compared to young. Increased non-specific inflammation observed in the skin of older adults negatively correlated with vitamin D sufficiency. We showed that vitamin D
    Conclusion: Vitamin D
    Language English
    Publishing date 2020-11-25
    Publishing country England
    Document type Journal Article
    ISSN 2732-4303
    ISSN (online) 2732-4303
    DOI 10.1093/immadv/ltaa008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top